Omnicell Q3 Revenue Climbs, Net Income Dips Amid Debt Repayment

TL;DR

**OMCL's revenue growth is solid, but the massive cash outflow for debt and buybacks makes me cautious on short-term liquidity.**

AI Summary

Omnicell, Inc. reported total revenues of $310.631 million for the three months ended September 30, 2025, an increase from $282.420 million in the same period of 2024. Product revenues rose to $177.498 million from $158.361 million, and service revenues increased to $133.133 million from $124.059 million. Net income for the quarter decreased to $5.462 million ($0.12 per diluted share) from $8.630 million ($0.19 per diluted share) in Q3 2024. For the nine months ended September 30, 2025, total revenues were $870.861 million, up from $805.359 million in the prior year, and the company swung to a net income of $4.078 million ($0.09 per diluted share) from a net loss of $3.311 million ($0.07 per diluted share) in the first nine months of 2024. Cash and cash equivalents significantly decreased to $180.053 million as of September 30, 2025, from $369.201 million at December 31, 2024, primarily due to the repayment of $175.000 million in convertible senior notes due 2025 and $77.600 million in common stock repurchases. Operating expenses increased to $126.259 million for the quarter from $115.704 million in Q3 2024, driven by higher selling, general, and administrative expenses of $102.238 million.

Why It Matters

Omnicell's revenue growth, particularly in product sales, indicates continued demand for its medication management solutions in the healthcare industry, which is positive for investors. However, the significant reduction in cash and cash equivalents, driven by the $175 million convertible senior notes repayment and $77.6 million in share repurchases, suggests a strategic deleveraging and shareholder return focus, but also reduces immediate liquidity. This could impact future investment capacity or financial flexibility compared to competitors. Employees might see this as a stable outlook given revenue growth, while customers benefit from ongoing product development in a critical sector. The broader market will watch how Omnicell balances growth investments with capital returns in a competitive healthcare technology landscape.

Risk Assessment

Risk Level: medium — The company's cash and cash equivalents decreased significantly from $369.201 million at December 31, 2024, to $180.053 million at September 30, 2025, a 51.3% reduction. This substantial decline in liquidity, primarily due to the $175.000 million repayment of convertible senior notes and $77.600 million in common stock repurchases, presents a medium-term liquidity risk, despite the positive net income for the nine months ended September 30, 2025.

Analyst Insight

Investors should monitor Omnicell's cash flow and liquidity closely in upcoming quarters, especially given the substantial debt repayment and share repurchases. While these actions can be positive long-term, the immediate impact on cash reserves warrants attention for future growth investments and operational flexibility.

Financial Highlights

debt To Equity

0.60

revenue

$310,631,000

operating Margin

14.5%

total Assets

$1,948,597,000

total Debt

$334,592,000

net Income

$5,462,000

eps

$0.12

gross Margin

43.3%

cash Position

$180,053,000

revenue Growth

+10.0%

Revenue Breakdown

Key Numbers

• $310.631M — Total Revenues (Q3 2025) (Increased from $282.420M in Q3 2024)
• $5.462M — Net Income (Q3 2025) (Decreased from $8.630M in Q3 2024)
• $4.078M — Net Income (YTD Q3 2025) (Swung from a net loss of $3.311M in YTD Q3 2024)
• $180.053M — Cash and Cash Equivalents (Sep 30, 2025) (Decreased from $369.201M at Dec 31, 2024)
• $175.000M — Repayment of Convertible Senior Notes (Major cash outflow in financing activities)
• $77.600M — Common Stock Repurchases (Significant cash outflow in financing activities)
• 44,876,522 — Shares Outstanding (Oct 29, 2025) (Reflects share repurchases)
• $0.12 — Diluted EPS (Q3 2025) (Decreased from $0.19 in Q3 2024)
• $0.09 — Diluted EPS (YTD Q3 2025) (Improved from $(0.07) in YTD Q3 2024)
• $96.946M — Net Cash Provided by Operating Activities (YTD Q3 2025) (Decreased from $131.407M in YTD Q3 2024)

Key Players & Entities

• OMNICELL, INC. (company) — Registrant
• SEC (regulator) — U.S. Securities and Exchange Commission
• NASDAQ Global Select Market (company) — Exchange where Common Stock is registered
• FASB (regulator) — Financial Accounting Standards Board
• Chief Executive Officer (person) — Chief Operating Decision Maker (CODM)
• $175,000 (dollar_amount) — Repayment of convertible senior notes due 2025
• $77,600 (dollar_amount) — Common stock repurchases
• $180,053 (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $369,201 (dollar_amount) — Cash and cash equivalents as of December 31, 2024
• $5,462 (dollar_amount) — Net income for the three months ended September 30, 2025

FAQ

Risk Factors

• Supply Chain Disruptions [medium — operational]: The company relies on a global supply chain for its products. Disruptions due to geopolitical events, natural disasters, or supplier issues could impact inventory levels and the ability to meet customer demand, potentially affecting revenue and profitability.
• Healthcare Regulatory Changes [medium — regulatory]: Omnicell operates in the highly regulated healthcare industry. Changes in healthcare laws, reimbursement policies, or data privacy regulations (like HIPAA) could increase compliance costs or impact the demand for its solutions.
• Competition and Technological Advancements [medium — market]: The medication management market is competitive. Failure to innovate and keep pace with technological advancements, or a loss of market share to competitors, could negatively impact financial performance.
• Interest Rate and Debt Management [low — financial]: The company has outstanding convertible senior notes. Changes in interest rates could affect the cost of debt, and the need to manage debt obligations, including potential refinancing or repayment, poses financial risk.
• Cybersecurity Threats [high — operational]: As a provider of healthcare technology solutions, Omnicell is a target for cybersecurity threats. A breach could compromise sensitive patient data, leading to significant financial penalties, reputational damage, and loss of customer trust.

Industry Context

Omnicell operates in the healthcare technology sector, specifically focusing on medication management and adherence solutions for hospitals and pharmacies. The industry is characterized by increasing demand for efficiency, patient safety, and cost reduction in healthcare delivery. Key trends include the adoption of automation, data analytics for improved patient outcomes, and integration with broader health IT systems.

Regulatory Implications

As a healthcare technology provider, Omnicell is subject to stringent regulations concerning data privacy (HIPAA) and the security of medical devices. Compliance with these regulations is critical to avoid significant fines and reputational damage. Changes in healthcare policy or reimbursement models could also impact the adoption and profitability of its solutions.

What Investors Should Do

1. Monitor operating expense trends, particularly SG&A.
2. Analyze the impact of cash outflows on future operations and investments.
3. Evaluate the sustainability of revenue growth against cost increases.

Key Dates

• 2025-09-30: End of Q3 2025 — Reporting period for the latest financial results, showing revenue growth but a decline in net income compared to Q3 2024.
• 2025-12-31: End of Fiscal Year 2024 — Reference point for the beginning cash balance ($369.201M) before significant outflows in 2025.
• 2025-02-27: Filing of 2024 10-K — Provided audited financial statements and context for the current period's unaudited statements.

Glossary

Convertible senior notes

Debt securities that can be converted into a predetermined amount of the issuer's equity (common stock). (Omnicell repaid $175 million of these notes, significantly impacting its cash position.)

Treasury stock

Stock that a company has repurchased from the open market. (The company's treasury stock increased significantly, indicating substantial share repurchases.)

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its net assets. (Represents a significant portion of Omnicell's assets, indicating past acquisitions.)

Deferred revenues

Revenue that has been received by the company but not yet earned. (An increase in deferred revenues suggests future revenue streams from unfulfilled service obligations.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Omnicell has demonstrated strong revenue growth, with total revenues increasing from $805.359 million to $870.861 million. The company also successfully transitioned from a net loss of $3.311 million to a net income of $4.078 million year-to-date. However, Q3 2025 saw a decrease in net income and EPS compared to Q3 2024, despite revenue increases, indicating rising operating costs. The cash position has significantly diminished due to strategic debt repayment and share repurchases.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value OMCL NASDAQ Global Select Mar

Filing Documents

• omcl-20250930.htm (10-Q) — 1485KB
• exhibit101q3-25.htm (EX-10.1) — 29KB
• exhibit311q3-25.htm (EX-31.1) — 10KB
• exhibit312q3-25.htm (EX-31.2) — 10KB
• exhibit321q3-25.htm (EX-32.1) — 7KB
• image_0.jpg (GRAPHIC) — 13KB
• image_1.jpg (GRAPHIC) — 8KB
• 0000926326-25-000031.txt ( ) — 8773KB
• omcl-20250930.xsd (EX-101.SCH) — 63KB
• omcl-20250930_cal.xml (EX-101.CAL) — 98KB
• omcl-20250930_def.xml (EX-101.DEF) — 279KB
• omcl-20250930_lab.xml (EX-101.LAB) — 767KB
• omcl-20250930_pre.xml (EX-101.PRE) — 556KB
• omcl-20250930_htm.xml (XML) — 1262KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 43 PART II OTHER INFORMATION 44 Item 1.

Legal Proceedings

Legal Proceedings 44 Item 1A.

Risk Factors

Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46 Item 3. Defaults Upon Senior Securities 46 Item 4. Mine Safety Disclosures 46 Item 5. Other Information 46 Item 6. Exhibits 47 Signature 48 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) OMNICELL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) September 30, 2025 December 31, 2024 (In thousands, except par value) ASSETS Current assets: Cash and cash equivalents $ 180,053 $ 369,201 Accounts receivable and unbilled receivables, net of allowances of $ 10,147 and $ 6,645 , respectively 245,720 256,398 Inventories 107,429 88,659 Prepaid expenses 30,247 25,942 Other current assets 96,171 75,293 Total current assets 659,620 815,493 Property and equipment, net 119,612 112,692 Long-term investment in sales-type leases, net 54,318 52,744 Operating lease right-of-use assets 26,092 25,607 Goodwill 737,872 734,727 Intangible assets, net 172,044 188,266 Long-term deferred tax assets 56,391 57,469 Prepaid commissions 52,559 54,656 Other long-term assets 70,089 79,306 Total assets $ 1,948,597 $ 2,120,960 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 62,486 $ 51,782 Accrued compensation 49,983 60,307 Accrued liabilities 165,342 167,895 Deferred revenues 178,777 141,370 Convertible senior notes, net — 174,324 Total current liabilities 456,588 595,678 Long-term deferred revenues 66,723 76,123 Long-term deferred tax liabilities 1,263 1,108 Long-term operating lease liabilities 27,600 31,123 Other long-term liabilities 8,227 7,218 Convertible senior notes, net 167,294 166,397 Total liabilities 727,695 877,647 Commitments and contingencies (Note 14) Stockholders' equity: Preferred stock, $ 0.001 par value, 5,000 shares authorized; no shares issued — — Common stock, $ 0.001 par value, 100,000 shares authorized; 57,682 and 56,665 shares issued; 44,876 and 46,382 shares outstanding, respectively 58 57 Treasury stock at cost, 12,806 and 10,283 shares outstanding, respectively ( 368,361 ) ( 290,319 ) Additional paid-in capital 1,211,495 1,167,882 Retained earnings 386,966 382,888 Accumulated other comprehensive loss ( 9,256

Business

Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company's major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company's market is primarily located in the United States. "Omnicell" or the "Company" refer to Omnicell, Inc. and its subsidiaries, collectively. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2025 and December 31, 2024, and the results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2025 and 2024, and cash flows for the nine months ended September 30, 2025 and 2024. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025. The Company's results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2025, and cash flows for the nine months ended September 30, 2025 are not necessarily indicative of results that may be expected for the year ending December 31, 2025, or for any future period. Principles of Consolidation The Condensed C

View Full Filing

View this 10-Q filing on SEC EDGAR